tbuckley/cabot-search huggingface dataset:
As ondas de calor de 2003 na Europa
Authors: T Kosatsky
Journal: Eurosurveillance (2005)

O numero atual de Eurosurveillance apresenta dados adicionais aos notificados no inicio de 2004, durante e imediatamente depois das ondas de calor do verao de 2003 [1], com um excesso estimado de 22 080 obitos para a Inglaterra e Gales, Franca, Italia e Portugal. Enquanto quase nao mudaram as estimativas para Inglaterra e Gales [2], Franca [3] e Portugal [4] comparadas com as previas informacoes, devem ser acrescentados 6595-8648 obitos em excesso para Espanha [5], dos quais 54%, ou seja entre 3574 e 4687, ocorreram em Agosto; assim como 1400-2200 nos Paises Baixos [6], dos quais aproximadamente 500 ocorreram durante a onda de calor entre 31 de Julho e 13 de Agosto. Os dados para a Italia, correspondentes aqui as cidades de Bolonha, Milao, Roma e Turino, sao compativeis com as estimativas anteriores, de 3134 obitos em 21 capitais regionais para o periodo entre 1 de Junho e 15 de Agosto [7]. Por entanto, o Instituto nacional italiano de estatistica assinalou um excesso de 19 780 obitos em todo o pais entre Junho e Setembro de 2003 comparado com 2002 [8]. Outros relatorios mencionam cerca de 1250 obitos ligados a onda de calor na Belgica durante o verano de 2003 [9], um excesso de 975 obitos entre Junho e Agosto na Suica [10], e de 1410 entre o 1° e o 24 de Agosto em Baden-Wurttemberg (Alemanha) [11]. Actualmente, pode-se pensar que, a vista da confirmacao dos obitos associados a onda de calor, entre Inglaterra e Gales, Franca, Italia e Portugal, o numero estimado de 22 080 obitos em excesso no principio de Agosto tem que ser revisto e acrescido de 50% para toda Europa occidental. Este aumento poderia ir ate 100% se forem consideradas as ondas de calor de Junho e Julho 2003.
MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program
Authors: F. Grossi, L. Crinò, A. Delmonte, D. Turci, D. Signorelli, F. De Marinis, H. Soto Parra, D. Galetta, F. Cappuzzo, F. Sperandi, M. Tiseo, G. Puppo, F. Roila, M.R. Migliorino, G. Tonini, F. Cognetti, A. Santoro, D. Tassinari, A. Scoppola, D. Giannarelli, E. Cortesi
Journal: Journal of Thoracic Oncology (2017)
Incidence des cas de Sida dans les institutions pénitentiaires espagnoles
Authors: E Acin, P. Gomez, P. Hernando, I Corella
Journal: Eurosurveillance (2003)

Trois sources d'information utilisees dans la surveillance du Sida dans les prisons espagnoles ont ete utilisees pour entreprendre une etude de capture-recapture. Les resultats montrent que le registre des cas de Sida sous-estime largement l'incidence de cette maladie dans les prisons, puisqu'il ne couvre qu'a peine 50% des cas. Cette etude souligne la necessite d'utiliser des donnees complementaires au RCS pour evaluer l'incidence reelle du Sida dans les prisons en Espagne.
Las consecuencias de la ola de calor del verano de 2003 sobre la mortalidad en los Países-Bajos
Authors: J Garssen, C Harmsen, J De Beer
Journal: Eurosurveillance (2005)

En los Paises Bajos, durante el verano de 2003, entre 1.400 y 2.200 defunciones podrian haber sido asociadas al calor. El hecho que las temperaturas maximas hayan sido inferiores a las de otros paises europeos y que hayan ocurrido en areas menos pobladas, puede explicar cifras de mortalidad relativamente menos dramaticas. El aumento temporal de las tasas de mortalidad se debe solo en parte a un desplazamiento de la mortalidad. La mayor parte de las defunciones asociadas al calor se observaron en personas mayores en residencias de la tercera edad.
Campaña de vacunación tras un aumento en la incidencia de enfermedades meningocócicas del serogrupo C en el departamento de Puy-de-Dôme (Francia)
Authors: D Lévy-Bruhl, A Perrocheau, M Mora, M K Taha, S Dromell-Chabrier, I Quatresous
Journal: Eurosurveillance (2002)

En el departamento de Puy-de-Dome, Francia, se declararon 17 casos de enfermedad meningococica invasiva C entre marzo de 2001 y la primera semana de 2002. De los 15 casos confirmados, 11 (73%) fueron del serogrupo C, 2 (13%) del serogrupo B y 2 no se pudieron identificar. El rapido aumento registrado en el numero de casos en un periodo de baja endemicidad para el resto del pais unido a la gravedad de la enfermedad (tasa de letalidad del 27%, purpura fulminante 64%) llevo a las autoridades sanitarias a poner en marcha una campana de vacunacion para ninos y jovenes adultos, desde los 2 meses hasta los 20 anos de edad que residiesen en una zona limitada del departamento. Entre 16/01/02 y 09/02/02 fueron inmunizadas unas 80.000 personas. De los 1.390 efectos secundarios inmediatos, mas de la mitad fueron cefaleas y mareos. Desde el 6 de enero hasta mediados de marzo, no se han declarado otros casos de enfermedad meningococica.
Nathaniel Hawthorne’s “The Birthmark”
Authors: Elizabeth J. Usedom
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
P2.02-068 BRG1 and p53 Expression in Resected Stage I – III Non-Small Cell Lung Cancer
Authors: A. Elegbede, M. Koebel, A. D'Silva, M. Dean, E. Enwere, R. Tudor, A. Gibson, H. Li, S. Otsuka, G. Bebb
Journal: Journal of Thoracic Oncology (2017)
Epidemiología del tétanos en Italia en los años 1971-2000
Authors: B Pedalino, B Cotter, M L Ciofi Degli Atti, D Mandolini, S Parroccini, S Salmaso
Journal: Eurosurveillance (2002)

La incidencia declarada de tetanos en Italia disminuyo de 0,5/100.000 habitantes en los anos setenta a 0,2/100.000 en los anos noventa. En este periodo de tiempo, la tasa de mortalidad disminuyo de 68% a 39%. Italia tiene el mayor numero de casos declarados de tetanos en los paises europeos. Las mujeres mayores son las mas afectadas: la proporcion de mujeres mayores de 64 anos entre los casos declarados ha aumentado del 60% en los anos setenta al 76% en los anos noventa. Es preciso realizar campanas de vacunacion dirigidas a este grupo, asi como mejorar la vigilancia del tetanos para que se identifiquen otros grupos de poblacion de riesgo
EXTH-12. REPURPOSING PROPRANOLOL AS AN ANTI-TUMOR AGENT FOR VON HIPPEL-LINDAU DISEASE
Authors: Matthew Shepard, Alejandro Bugarini, Qi Zhang, Zhengping Zhuang, Prashant Chittiboina
Journal: Neuro-Oncology (2017)

von Hippel-Lindau disease (VHL) is a tumor predisposition syndrome characterized by the development of CNS hemangioblastomas (VHL-HB) and renal cell carcinomas (RCC) due to hypoxia inducible factor activation. Due to a lack of effective medical therapies for VHL, HBs/RCCs may lead to significant morbidity and mortality, ultimately necessitating numerous neurologic and renal surgeries. Propranolol is an FDA approved beta-1/2 antagonist discovered to harbor anti-tumor effects for infantile hemangiomas (IH), and possibly VHL-HBs. We investigated whether propranolol has anti-tumor activity against VHL-related HBs/RCCs. Patient-derived VHL-HBs or 786-0-VHL-/- RCC cells were treated with clinically relevant concentrations of propranolol in-vitro and assessed with viability assays, flow cytometry, QT-PCR and western blots. In-vivo confirmation of propranolol anti-tumor activity was confirmed in athymic nude mice bearing 786-0 xenograft tumors. Lastly, patients enrolled in a VHL natural history study (NCT00005902) who were also on propranolol were identified. Propranolol activity against VHL-HBs was assessed retrospectively with volumetric HB growth kinetic analysis. Propranolol decreased HB and RCC viability in-vitro with an IC50 of 100µM and 200µM, respectively. Similar to prior reports in IH, propranolol induced apoptosis and led to increased VEGF-A mRNA expression in patient-derived VHL-HBs and 786-0 cells. Intracellular VEGF protein levels were not affected by propranolol. Tumor bearing nude mice exposed to propranolol had slower tumor progression compared to controls (33% volume reduction at 7 days, p < 0.005). Four patients harboring 76 CNS-HBs started propranolol therapy during a longitudinal VHL-HB study. HBs in these patients tended to grow slower (m=0.19 versus 0.13, p=0.4) during propranolol treatment. Propranolol decreases VHL-HB/RCC viability in-vitro likely by apoptosis and modulation of VEGF expression. Propranolol abrogates 786-0 xenograft tumor progression in-vivo and retrospective clinical data suggests that propranolol curtails HB growth. These results suggest propranolol may play a role in treatment of VHL-related tumors.
ACTR-50. CLINICAL TRIALS WITH DIANHYDROGALACTITOL (VAL-083) IN MGMT-UNMETHYLATED GLIOBLASTOMA
Authors: Jeffrey Bacha, Anne Steino, John Langlands, Sarath Kanekal, Richard Schwartz, Lorena Lopez, Barbara J O’Brien, Zhongping Chen, Marta Penas-Prado, Dennis Brown
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard-of-care includes surgery, radiation and treatment with temozolomide (TMZ), however nearly all tumors recur and the prognosis for recurrent GBM is dismal. Resistance to TMZ is correlated with expression of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT), which is highly expressed in a majority of GBM tumors. Dianhydrogalactitol (VAL-083) is a first-in-class bi-functional DNA-targeting agent that exhibited activity against GBM in NCI-sponsored clinical trials both as a single agent and in combination with radiotherapy. VAL-083 readily crosses the blood-brain barrier and accumulates in brain tumor tissue. We have demonstrated that VAL-083 targets N7-Guanine and rapidly induces interstrand DNA cross-links, leading to DNA double-strand breaks, S/G2 cell-cycle arrest and cell death in GBM cell lines and GBM cancer stem cells (CSCs) in vitro. This unique N7-guanine targeting mechanism not only circumvents MGMT-mediated chemo-resistance but also maintains cytotoxic activity in cancer cells deficient in mismatch repair (MMR). These data suggest VAL-083 may offer a superior chemotherapeutic alternative in the treatment of MGMT-unmethylated or MMR deficient GBM. Here, we provide an update of ongoing clinical trials with VAL-083 in MGMT-unmethylated GBM: i) a single-arm, biomarker-driven, Phase II study to determine if VAL-083 treatment of MGMT-unmethylated adult GBM patients at first recurrence/progression, prior to bevacizumab improves survival compared to historical lomustine control (clinicaltrials.gov identifier: NCT02717962); ii) a single-arm, biomarker-driven, Phase II study to confirm the tolerability and efficacy of VAL-083 in combination with radiotherapy in newly diagnosed MGMT-unmethylated GBM patients (clinicaltrials.gov identifier: NCT03050736). The results of these studies may support a new treatment paradigm in for the treatment of MGMT-unmethylated GBM.
Efficacy and patient acceptability of the DigniCaP ScalpCooler to prevent hair loss in breast cancer patients receiving adjuvant chemotherapy
Authors: F. Carla, L. Vassalli, R. Pedersini, E. Conti, M. Tagliani, A. Baronchelli, D. Ragni, E. Lombardi, V. Amoroso, B. Berta, M. Gelmi, F. Rodella, C. Fogazzi, M. Claps, M. Romelli, A. Berruti, E.L. Simoncini
Journal: Annals of Oncology (2017)
Une épidémie de Campylobacter jejuni dans une école de Madrid, Espagne
Authors: M Jiménez, P Soler, J D Venanzi, P Canté, C Varela, J. F. Martinez Navarro
Journal: Eurosurveillance (2005)

Une epidemie de gastroenterite due a une infection a Campylobacter a ete identifiee en mai 2003 dans une ecole de Madrid, Espagne. Quatre-vingt-un cas ont ete identifies dans une population de 253 personnes. Une etude de cohorte retrospective a montre qu’une creme dessert preparee avec du lait UHT (ultra high temperature) etait associee a la maladie (RR=3,15; 95% CI : 1,25-7,93). Cette creme a probablement ete contaminee par Campylobacter jejuni lors de la preparation d’un poulet cru la veille dans la meme cuisine. Les recommandations des auteurs etaient de rappeler periodiquement au chef d’etablissement les dispositions a prendre en cas de suspicion d’une epidemie, d’inclure la surveillance des methodes de travail quotidiennes d’un employe de cuisine dans chaque investigation environnementale afin d’identifier tout comportement a risque ; de mettre en place des analyses microbiologiques des surfaces et des ustensiles des cuisines collectives et d’ameliorer l’education des employes de cuisine en matiere de securite sanitaire.
Prognostic factors associated with survival and recurrence in resectable gastroesophageal cancer: retrospective analysis of 338 patients operated at the Hospital of Cremona in ten years' time
Authors: M. Ghidini, B.M. Donida, D. Lomiento, M. Ratti, C. Pizzo, F. Aldighieri, L. Toppo, V. Ranieri, C. Senti, G. Tanzi, M. Martinotti, R. Passalacqua, G. Tomasello, M. Rovatti
Journal: Annals of Oncology (2017)
CMET-06. ACTIVE COMBINED THERAPY IS BENEFICIAL FOR LEPTOMENINGEAL METASTASIS IN NSCLC WITH LOW KPS SCORES
Authors: Linbo Cai, Junjie Zhen
Journal: Neuro-Oncology (2017)

Leptomeningeal metastasis is one of the most severe stages of non-small cell lung cancer (NSCLC). This study aimed to assess active combined therapy for leptomeningeal metastasis in NSCLC with low Karnofsky performance scale (KPS) scores. Clinical characteristics, neurological response to treatment, headache score, and follow-up data of 19 patients with leptomeningeal metastasis in NSCLC were retrospectively assessed. The patients’ median age was 56 years. Nine (47.4%) and sixteen (84.2%) cases were diagnosed by cerebrospinal fluid cytology and MRI, respectively. Treatment methods included radiotherapy, TMZ chemotherapy, systemic chemotherapy, EGFR-TKI targeted therapy, dehydration, and analgesic treatment. Median follow-up time was 6 months, with one case lost to follow-up; 15 patients died and 3 survived. Overall survival (OS) was 8 months; meanwhile, 6-month and 1-year survival rates were 67.7% and 32.2%, respectively. Median KPS scores before and after treatment were 50 and 80 points, respectively (P=0.012); 12 (63.2%) and 7 (36.8%) cases had KPS<60 points and KPS≥60 points pretreatment, respectively. Median OS rates in patients with KPS<60 and KPS≥60 were 4 and 9 months, respectively (P=0.127). After 2 weeks of treatment, 13 (68.4%), 5 (26.3%), and 1 (5.3%) cases showed remission, stability, and progression, respectively. ‘Headache’ was the main complaint in 16 cases before treatment, with VAS scores of 6–9. Median time to complete remission was 26 days. From week 2 of treatment, VAS scores decreased significantly. Active combined therapy is beneficial for leptomeningeal metastasis in NSCLC with low KPS scores.
La política de vacunación contra la hepatitis A para los viajeros a Egipto en ocho países de Europa, 2004
Authors: M Ward, K Borgen, A Mazick, M Muehlen
Journal: Eurosurveillance (2006)

En 2004 se produjo un brote de hepatitis A en turistas europeos de regreso de Egipto. Las tasas de ataque de la infeccion fueron muy diferentes segun el pais de procedencia de los turistas. Para determinar la causa de esas diferencias, se inicio un estudio con los objetivos siguientes : (a) reunir informacion sobre las politicas nacionales de prevencion de la hepatitis A para los viajeros a Egipto, y (b) informacion sobre las practicas de notificacion de la hepatitis A en dichos paises. Se elaboro un cuestionario y se envio a 13 paises de Europa. Los ocho paises que respondieron habian todos publicado recomendaciones para la prevencion de la hepatitis A asociada a los viajes. Entre 2001 y 2003, el 40% (entre 4 y 51) de los casos de hepatitis A notificados cada ano estaban asociados con los viajes al extranjero, a pesar de que todos estos paises recomendaran la vacunacion contra la hepatitis A para viajeros de vacaciones a Egipto. No habia ninguna definicion de caso estandarizada para la notificacion de casos confirmados de hepatitis A en los paises que declararon esos casos. Teniendo en cuenta el numero creciente de turistas hacia paises lejanos, es previsible un aumento de las infecciones asociadas a viajes. Sera necesario buscar nuevas formas de convencer a los viajeros para que consulten un medico antes de partir y que sigan sus consejos. Ademas, recomendamos usar la definicion de caso de la Comision Europea para la notificacion de casos confirmados de hepatitis A.
P1.07-028 Determination of Soluble PD-L1 as a Potential Biomarker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC)
Authors: A. Barba Joaquín, C. Zamora Atenza, S. Vidal Alcorisa, I. Sullivan, G. Anguera Palacios, M.a. Ortiz De Juana, M. Andrés Granyò, A. Virgili Manrique, N. Dueñas Cid, A. Vethencourt Casado, L. Del Carpio Huerta, P. Gomila Pons, S. Camacho Arellano, S. Moron Asensio, M. Riudavets Melia, C. Molto Valiente, A. Callejo Perez, M. Majem Tarruella
Journal: Journal of Thoracic Oncology (2017)
P2.01-005 A Randomized Phase II Trial of Erlotinib vs S-1 in Patients with NSCLC as Third- or Fourth-Line Therapy (HOT1002)
Authors: Y. Kawai, H. Asahina, Y. Ikezawa, S. Oizumi, T. Ogi, M. Watanabe, T. Amano, H. Dosaka-Akita, H. Isobe, M. Nishimura
Journal: Journal of Thoracic Oncology (2017)
MA 03.05 Bevacizumab Combined with Chemotherapy for Patients with Advanced NSCLC and Brain Metastasis. A French Cohort Study
Authors: J. Bennouna, L. Falchero, R. Schott, F. Bonnetain, M. Coudert, B. Ben Hadj Yahia, C. Chouaid
Journal: Journal of Thoracic Oncology (2017)
Efficacy and Safety of Tamsulosin in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Authors: Zhangqun Ye, Guohua Zeng, Huan Yang, Kun Tang, Xiaochun Zhang, Hong Li, Weibing Li, Zhong Wu, Lingwu Chen, Xingfa Chen, Xiankui Liu, Yaoliang Deng, Tiejun Pan, Jinchun Xing, Shusheng Wang, Yue Cheng, Xiaojian Gu, Wenxi Gao, Jianggen Yang, Yonghai Zhang, Qiwu Mi, Lin Qi, Jiongming Li, Weilie Hu, Peiyu Liang, Zhaolin Sun, Changbao Xu, Yongfu Long, Yongbin Liao, Siping Liu, Guoqing Liu, Xun Xu, Wei He, Zhiqiang Chen, Hua Xu
Journal: European Urology (2017)
EXTH-54. METFORMIN ACTS SYNERGISTICALLY WITH GALLIUM MALTOLATE TO INHIBIT THE PROLIFERATION OF GLIOBLASTOMA CELLS BY ACTION ON MITOCHONDRIAL FUNCTION
Authors: Hisham S Alhajala, Mona M Al-Gizawiy, Kathleen M Schmainda, Christopher R Chitambar
Journal: Neuro-Oncology (2017)

There is a vital need for new therapeutics to treat glioblastoma (GBM). Recently, we showed that gallium maltolate (GaM) inhibits the iron-dependent growth of GBM in vitro and in vivo. Here, we investigated whether metformin, an antidiabetic drug that can enter the brain, could potentiate the anti-GBM action of GaM. Adult D54 and U87-MG GBM cells were incubated with GaM and metformin, alone or in combination, for various times. Cell growth was measured by cytotoxicity assay. Drug synergy was calculated using Calcusyn computer program. Cellular mitochondrial function was measured using a Seahorse XFp Extracellular Flux Analyzer. Transferrin (Tf) receptor (TfR, iron uptake protein) and ferritin (Ftn, iron storage protein) levels were measured in GaM- and metformin–treated cells by 125I-Tf binding assay and Western blot. Metformin (0–2 mM) and GaM (0–100 µM)) individually inhibited the growth of U87 and D54 cells in a dose- and time-dependent manner. In combination, the drugs inhibited cell growth with a Combination Index (CI) of <1, consistent with drug synergy. At 24 h of incubation, prior to a decrease in proliferation, GaM and metformin individually suppressed cellular oxygen consumption rate (OCR) and their combination further blocked cellular OCR, consistent with synergistic inhibition of mitochondrial function. Cellular H-Ftn levels were decreased by metformin and increased by GaM. Metformin and GaM increased TfR expression 2 -3 fold whereas their combination increased TfR by only 1.2-fold above control cells. Metformin synergistically enhances GaM’s activity against glioblastoma. Both drugs perturb tumor iron homeostasis, which leads to changes in iron uptake and storage proteins. Metformin inhibits mitochondrial complex 1, whereas GaM inhibits Fe-dependent mitochondrial function and ribonucleotide reductase. Together, they synergistically inhibit mitochondrial function and block cell proliferation in GBM. Further studies will examine the potential of combination metformin and GaM in an animal model.
ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia
Authors: Rajesh Pahwa, Robert A. Hauser
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal